Alterola Biotech Inc   (ALTA)
Other Ticker:  
Price: $0.0000 $0.00 %
Day's High: 0.00 Week Perf:
Day's Low: $ 0.00 30 Day Perf:
Volume (M): 0 52 Wk High: $ 0.00
Volume (M$): $ 0 52 Wk Avg: $0.00
Open: $0.00 52 Wk Low: $0.00

 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) 1,265
 Employees 1
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -3
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Alterola Biotech Inc

Our plan is to use our IP and develop and market nutraceutical/functional chewing gum and in the future medicinal chewing gum. We are ardently researching new ways to use chewing gum as a delivery system, expanding on the kinds of applications chewing gum has been used for in the past. We initially expected to reveal functional chewing gum for new applications, but we were not able to do so. We will first need to raise additional capital to develop our chewing gum for the delivery of medicines.

We acquired intellectual property relating to certain chewing gum compositions having appetite suppressant activity (the “IP”). Following the acquisition of the IP, we commenced pursuing the development of chewing gums for the delivery of nutraceutical/functional ingredients for applications such as appetite suppressant, cholesterol suppressant, vitamin delivery, antioxidant delivery and motion sickness suppressant.

Our mission is to improve the health and quality of life for millions of people all over the world who are unable to or have difficulty with swallowing tablets. As much as 40% of the adult population and an even greater percentage of the adolescent population have difficulties swallowing pills, and we believe our solutions will greatly benefit them.

Presently, we are focused on nutrition and health chewing gum with natural based ingredients. The products below are currently under development and we are working to file patents to protect the ingredients in these products.

Appetite suppressor
Cholesterol suppressor
Antioxidant gum
Motion sickness suppressor
Vitamin gum
In order to implement our business plan, however, we will need to raise funds. We were able to secure small loans to pay the legal and accounting fees needed to keep our reporting filings current with the Securities and Exchange Commission. We will need more funds to meet our timetable of introducing Nutraceutical/functional chewing gum. We expect that we will need capital of $500,000 to develop our products.

   Company Address: 47 Hamilton Square Birkenhead Merseyside 0
   Company Phone Number: 601 9477   Stock Exchange / Ticker: ALTA


Stock Performances by Major Competitors

5 Days Decrease / Increase
HAIN        0.73% 
MDLZ        0.14% 
NHMD        22.22% 
SMPL   -0.26%    
• View Complete Report

Alterola Biotech Inc

Operating Losses Surge for Alterola Biotech Inc in Q4 2023 Financial Report

Alterola Biotech Inc, a legal cannabis company, has recently released its financial report for the October to December 2023 reporting cycle. The shareholders have not anticipated any changes in revenue during this period. However, they have expressed concerns over the company's operating loss, which amounted to $-1.108947 million.
To better understand the current state of the company, it is important to compare its performance with previous quarters. In the third quarter of 2023, Alterola Biotech Inc reported an operating loss of $0.540621 million. This indicates a significant increase in losses during the October to December 2023 reporting cycle.

Alterola Biotech Inc

Legal Cannabis Company Smashes Expectations with Operating Deficit Shrinking to $-0.47 Million in Q3 2023

Date: January 15, 2024
In the wake of major players in the legal cannabis sector revealing their substantial earnings, attention now turns to smaller businesses within the industry. Among them, ALTA, a company operating principally in the progress stage, has recently reported an operating deficit of $-0.123155 million for the second quarter of 2024. While these losses may seem concerning, a closer look suggests an optimistic trajectory for the company's future performance.
Comparing ALTA's current performance to the same period in 2023, it becomes evident that the recent management strategies have significantly curbed losses. In the July to September 2023 financial span, the company managed to reduce losses to $-0.123 million from $-0.375 million the previous quarter. This highlights the company's commitment to refining its business model and demonstrating progress in terms of financial stability.

Alterola Biotech Inc

As One of Many Businesses, the ALTA Disclosed a Worrisome Operating Deficit and Revenue Uncertainty in its First Quarter 2024 Results

Alterola Biotech Inc, a prominent player in the legal cannabis sector, recently released its financial results for the first quarter of 2024. With no specified revenue and an operating deficit of $-0.58067 million, the company's current reporting season raises concerns among investors. This article aims to provide context about Alterola Biotech Inc's market position, stock performance, and the implications of its financial figures.
Operating Deficit and Revenue Uncertainty:
One of the major concerns highlighted in Alterola Biotech Inc's Q1 2024 report is the operating deficit of $-0.58067 million. Without any specified revenue, investors are eagerly awaiting additional business strategies as soon as possible. However, the shareholders seem less concerned about the company's current expertise, suggesting a willingness to see growth potential in Alterola Biotech Inc's future approach.

Alterola Biotech Inc

Alterola Biotech Inc Defies Expectations: Transforms $-1.75M Operating Deficit into Soaring Growth in Legal Cannabis Market

As a journalist covering the financial sector, it is always interesting to keep an eye on the big players in various industries. Recently, there has been significant attention given to the Legal Cannabis industry and its major players. However, it is important not to overlook the smaller companies that are also striving to make their mark in this rapidly expanding market.
One such company is Alterola Biotech Inc, which recently released its financial results for the fourth quarter of 2023. The company reported an operating deficit of $-1.75692 million during this period. While this may seem like cause for concern to some, it is actually a promising revelation for Alterola Biotech Inc.



About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com